In an important development, the Drugs Controller General of India (DCGI) on Thursday granted approval for the Phase 2 and 3 clinical trial of Bharat Biotech’s COVID-19 vaccine, Covaxin, in the age group of 2 to 18 years.It has been reported that the Indian firm will carry out these clinical trials in 525 healthy volunteers.The approval for clinical trials came two days after an expert panel gave a recommendation for conducting Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years.

In an important development, the Drugs Controller General of India (DCGI) on Thursday granted approval for the Phase 2 and 3 clinical trial of Bharat Biotech’s COVID-19 vaccine, Covaxin, in the age group of 2 to 18 years.It has been reported that the Indian firm will carry out these clinical trials in 525 healthy volunteers.The approval for clinical trials came two days after an expert panel gave a recommendation for conducting Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years.